Physician profile
Christopher E Hester
NPI 1407819162
$2,525.75
in general payments reported to CMS, 2019-2025
25 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $180 · 2021: $354 · 2022: $358 · 2023: $559 · 2024: $428 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $436.76 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $370.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $302.33 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $235.39 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $188.89 | 2019-2022 | |
| Abbott Laboratories | $105.07 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $99.50 | 2019-2023 | Farxiga |
| Amgen INC. | $96.05 | 2019-2025 | Krystexxa, Prolia, Evenity |
| Dexcom, INC. | $86.41 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $64.75 | 2022-2024 | |
| Urovant Sciences INC | $62.20 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $61.32 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $57.46 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Biohaven Pharmaceuticals, INC. | $57.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $49.64 | 2022-2025 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.21 | 2024-2025 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $35.57 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.40 | 2022-2023 | Combivent Respimat, Spiriva Respimat, Stiolto Respimat |
| Radius Health, INC. | $31.03 | 2020 | |
| Amarin Pharma, INC. | $25.84 | 2020 | |
| Apria Healthcare LLC | $20.00 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.89 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.60 | 2023 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.